Portfolio7 Oct 2013 22:04
Courtesy of rivaldo
This PEBI thread is partly due to its stake in Ampliphi Biosciences (APHB), in which I have a decent-sized holding. The APHB thread is here:
http://uk.advfn.com/cmn/fbb/thread.php3?id=25624085
PEBI's m/cap with 33.86m shares in issue is £2.37m at 7p.
At 30th June 2013 PEBI had £3.6m net assets, or 10.6p per share, comprising £2.92m of investments and £0.7m of uninvested cash.
Largest investments at 30th June 2013:
Synergy Pharmaceuticals Inc. 277,748 9.52% (plus £10k of warrants in 2012)
Summit Corporation plc 212,500 7.29% (when share price was around 4p, 15p at 20/9/13)
Arrowhead Research (ARWR) 207,364 7.11% (when share price was around $2, now $4.75)
Plethora Solutions Holdings 166,625 5.71% (when share price was around 2p, now 13p)
TrovaGene Inc. 137,224 4.70%
Pfizer Inc. 136,562 4.68%
Nektar Therapeutics 127,303 4.36%
Sanofi-ADR 91,349 3.13%
1,356,675 46.51%
Plus Ampliphi Biosciences (APHB) 60,000 (when share price was around 15c, now 55c).
From the above, shareholdings must be approximately:
SUMM : 5,300,000 shares @ 19.25p = £1.03m
PLE : 8,300,000 shares @ 14.2p = £1.18m
APHB : 500,000 shares @ $0.55 = £0.2m
ARWR : 100,000 shares @ $4.80 = £0.3m
SGYP : 64,000 shares @ $4.81 = £0.2m
TROV : 20,000 shares @ $7.00 = £0.1m
NKTR : 11,000 shares @ $13.74 = £0.1m
An info sheet from the 2012 Master Investor show lists the following additional holdings totalling approx. £1.55m:
Novartis : £156,000
Astellas Pharma : £134,000
Abbot Labs : £111,000
Merck : £91,000
Onyx Pharma : £86,000
H Lundebeck : £73,000
Immunocellar Therapeutics : £68k
Celgene : £68,000
Map Pharmaceuticals : £68,000
Eli Lilly : £67,000
Medivir : £66,000
Shire : £66,000
Rigel Pharmaceutical : £64,000
Polymedix : £54,000
Pharmathene : £52,000
Medivation : £51,000
Siga Technologies : £49,000
Sundry other holdings : £214,000, incl Miraculins, Synta, Spiritus, Pacific Biosciences, Biotime, Methylgene, Complete Genomics
Here's an old 23 minute interview with Jim Mellon re PEBI which notes that it has 20 holdings. He mentions Medivation, which has increased from $52 at 30/6 to $57.50 now:
http://sharecrazy.com/beta/athol-gold/6981/interview-iwth-jim-mellon-on-port-erin-bio-pharma